/ z9 b! A t1 I! M6 ?3 |- M2 j临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:/ A6 J% f* m5 g
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.3 I+ W$ @, F$ d8 Q% B http://www.ncbi.nlm.nih.gov/pubmed/229681844 I- [1 h! N6 I0 P' W! K4 S& V